查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年全球心臟消融設備市場
市場調查報告書
商品編碼
1140702

2022-2029 年全球心臟消融設備市場

Global Cardiac Ablation Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

心臟消融設備市場規模預計將在 2021 年達到 40.672 億美元，在 2029 年達到 108.943 億美元，在預測期間（2022-2029 年）以 12.85% 的複合年增長率增長。我來了。

心臟消融術，一種用於改變/改變導致心律異常的心臟組織功能的非侵入性手術。心臟消融有多種類型，包括導管消融、手術消融和混合手術導管消融。心臟消融用於心律管理、開放手術和其他應用。

市場動態

主要驅動因素是心律失常患病率的上升、老年人口的增長、保健意識的提高以及對非侵入性手術的需求不斷增加。

心律失常患病率的上升和研究活動的增加預計將推動市場增長。

預計心律失常的增加將推動市場。例如，根據 CDC2020 報告，每年有超過 750,000 人因房顫住院。該病每年還導致近 130,000 人死亡。因此，越來越多的心律失常病例正在推動市場。

預計在預測期內，不斷增長的老年人口將提振市場。許多國家目前正面臨與人口增長和老齡化相關的挑戰。根據聯合國經濟和社會事務部 2019 年人口司的數據，未來 30 年，全球 60 歲及以上人口將增加兩倍。根據世界衛生組織 (WHO) 的數據，65 歲及以上的人口預計將從 2010 年的 5.24 億增長到 2050 年的 15 億。一些慢性疾病的發病率，如心血管疾病和神經退行性疾□□病，往往與老年人口有關，並且變得越來越普遍。因此，老年人口的增加正在推動市場。

增加研究活動以確認消融設備的有效性和安全性也有望推動市場發展。例如，2019 年 8 月 19 日，約翰霍普金斯大學的科學家們將創建心臟上腔室的個性化數字複製品，並用它來指導對持續性心律失常患者的精準治療，我成功了。 Loyola 還測試了一種新的導管消融系統，該系統可以深入心肌。

嚴格的政府法規和副作用預計會阻礙市場增長。

缺乏熟練的醫護人員、嚴格的政府法規和副作用正在阻礙市場發展。其中，副作用的發生有望抑制市場。例如，中風、化學過敏、食道損傷和很少發生在普通人群中的完全心源性死亡。

行業分析

全球心臟消融設備市場根據各種行業因素（包括波特五力、監管分析、供應鏈分析、定價分析和未滿足的需求）對市場進行了深入分析。

細分分析

在全球心臟消融設備市場中，射頻消融設備部分預計將佔據最大的市場份額

按產品類型，全球心臟消融設備市場可細分為射頻 (RF) 消融設備、電消融設備、冷凍消融設備、超聲消融設備和微波消融設備。

電消融設備進一步細分為氬等離子體/束凝固器和不可逆電穿孔系統。由於研究活動的增加，預計電灼設備將具有較高的增長率。例如，在心律學會第 39 屆年度科學會議上展示其研究細節的研究人員 Heart Rhythm 已經開始了一項首次人體電穿孔消融研究，表明脈衝電場可以針對心房顫動中的特定組織進行報導。

冷凍消融設備進一步分為組織接觸探針和組織噴霧探針。由於最近主要參與者的批准、收購和合併，預計冷凍消融設備將推動市場發展。例如，2021年1月，美敦力宣布其DiamondTemp消融系統獲得美國FDA批准，用於治療復發性陣發性房顫患者。

超聲消融設備又分為高強度聚焦超聲消融器、磁共振引導聚焦超聲消融器和超聲消融系統。預計最近的政府批准將在預測期內推動市場。例如，2019 年，Acutus Medical 的 AcQMap 接觸地圖軟件獲得了歐洲的批准。該系統中的新型導管使用超聲和電組織傳導映射來提供心臟內部的新型電生理實時視圖。

全球心臟消融設備市場可按應用細分為心律管理、心臟直視手術等。

心律管理進一步分為心律失常、心房顫動和撲動以及心動過速。由於越來越多的研究和政府批准，預計心律管理部門將推動市場發展。 Loyola Medicine 是世界上僅有的兩個提供新型導管消融系統的中心之一，該系統用於改善稱為室性心動過速的危及生命的心律失常的預後。根據 2019 年 1 月 30 日發表在《核醫學雜誌》一月刊上的一項新研究，碘-123-間碘芐基胍 (123I-MIBG) SPECT 成像與心臟磁共振成像 (MRI) 相結合。如果是這樣，它可能會有所幫助識別容易發生心律失常的特定心臟組織亞群，使醫生能夠更好地抑制室性心動過速並縮短手術時間。通過這種方式，積極的研究活動正在推動市場。

區域分析

北美佔全球心臟消融設備市場最大的市場份額

從地理位置上看，全球心臟消融設備市場分為五個主要區域。北美、歐洲、亞太地區、拉丁美洲、中東和非洲。

由於心律失常的患病率不斷增加、基礎設施完善、外科導管的大規模採用、政府支持的增加以及患者意識的提高，北美在全球心臟消融設備市場佔據主導地位。預計市場規模將保持巨大在預測期內。

外科導管插入術的激增預計將提振市場。例如，根據美國心臟協會 (AHA) 的說法，導管消融術的成功率高達 90%，並發症風險低，並且可以讓患者在幾天內恢復正常活動。 Biosense-Webster、美敦力和波士頓科學等領先公司每年花費數百萬美元研究和開發新設備，以提高成功率並減少手術並發症。我在這裡。

心律失常病例的增加也推動了市場的發展。例如，2019 年，疾病控制和預防中心估計美國有 2.7 到 610 萬人患有心房顫動。因此，越來越多的心律失常病例正在推動市場。

心臟消融設備製造商的出現也推動了市場的發展。例如，2022 年 2 月，美敦力公佈了美國 FDA 批准的 Freezor 和 Freezor Xtra 心臟冷凍消融灶導管。這是 FDA 批准用於治療兒科 AV 結折返性心動過速的首批消融導管。

競爭格局

心臟消融設備市場由眾多參與者主導，例如波士頓科學公司、Epix Therapeutics、Acutus Medical、美敦力、AtriCure, Inc、Biosense Webster, Inc、St Jude Medical、雅培、西奈山健康系統公□□司。競爭激烈兇猛的。

主要參與者正在採取各種增長策略，例如產品發布、併購、合作夥伴關係和聯盟，這有助於全球心臟消融設備市場的增長。例如：

  • 2022 年 8 月，美敦力宣布收購 Affere Inc.。此次收購將使 Metronic 能夠擴大其心臟消融產品組合，以包括首個提供集成診斷和射頻消融解決方案的心臟標測和導航平台。
  • 2021 年 10 月，波士頓科學宣布收購 Bayliss Medical。此次收購擴大了波士頓科學公司的電生理學和心臟產品組合。
  • 2021 年 6 月，波士頓科學公司宣布收購 Farapulse 的股份。 Farapulse 的脈衝場消融系統的加入擴大了波士頓的電生理學產品組合。用於治療心房顫動的非熱消融系統。
  • 2021年1月，美敦力宣布DiamondTemp消融系統獲美國FDA批准用於治療復發性陣發性房顫患者。它是第一個獲得 FDA 批准的溫度可控灌注射頻消融系統。

值得關注的重點公司

波士頓科學公司

概覽 Boston 是一家跨國生物醫學工程公司。該公司生產用於介入心髒病學、神經血管介入、心臟外科、腫瘤外科、血管外科的醫療器械，並提供微創植入式心血管除顫器。成立於 1979 年，總部位於美國馬薩諸塞州。

產品組合

MetriQ 泵。允許消融手術的開放式灌注系統。有助於最大限度地提高開放灌注程序的成功率。使用先進的消融技術改善患者治療效果。

重大進展。 2021 年 1 月，波士頓科學公司宣布了一項收購移動心臟健康解決方案產品和服務的私人控股供應商預防解決方案公司的協議。

全球心臟消融設備市場報告包含大約 45 多個市場數據表、40 多個數字和 180 頁。

內容

第1章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第 4 章市場動態

  • 市場影響因素
    • 驅動程序
      • 心律失常發病率增加
      • 老年人口增加
    • 限制因素
      • 出現副作用
    • 商機
    • 影響分析

第5章行業分析

  • 波特五力分析
  • 監管分析
  • 供應鏈分析
  • 定價分析
  • 未滿足的需求分析

第 6 章按產品類型

  • 射頻 (RF) 消融
    • 溫控高頻消融器
    • 液冷式高頻消融器
    • 機器人導管操縱系統
  • 電烙術
    • 氬等離子/束流凝固器
    • 不可逆電穿孔系統
  • 冷凍消融
    • 組織接觸探針
    • 組織噴霧探針
  • 超聲消融
    • 高強度聚焦超聲消融器
    • 磁共振引導聚焦超聲消融器
    • 超聲波消融系統
  • 微波消融裝置
    • 微波熱處理裝置

第 7 章按應用程序

  • 心律管理
    • 心律失常
    • 心房顫動和撲動
    • 心動過速
  • 開腹手術
  • 其他

第 8 章最終用戶

  • 醫院
  • 門診手術中心
  • 診所
  • 其他

第 9 章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第 10 章競爭格局

  • 競爭場景
  • 市場定位/市場份額分析
  • 併購分析

第 11 章公司簡介

  • 波士頓科學公司
    • 公司概況
    • 產品組合和描述
    • 主要亮點
    • 財務摘要
  • Epix Therapeutics
  • Acutus Medical
  • Medtronic
  • AtriCure, Inc.
  • Biosense Webster, Inc.
  • St Jude Medical
  • Abbott
  • Mount Sinai Health System Inc

第12章 心臟消融設備的全球市場 - DataM

簡介目錄
Product Code: DMMD2046

Market Overview

Cardiac Ablation Devices Market size was valued US$ 4,067.2 million in 2021 and is estimated to reach US$ 10,894.3 million by 2029, growing at a CAGR of 12.85% during the forecast period (2022-2029).

Cardiac ablation, a non-invasive procedure to modify/alter the functions of the tissues in heart which causes abnormal heart rhythm. Catheter ablation, surgical ablation, and hybrid surgical catheter ablation are various types of cardiac ablation. Cardiac ablation is used in cardiac rhythm management, open surgery, and in other applications.

Market Dynamics

The major driving forces are the increasing number of people with cardiac arrhythmia, increasing geriatric population, rising healthcare awareness, and the growing demand for non-invasive procedures.

Increasing prevalence of cardiac arrhythmia and rising research activities are expected to drive market growth.

The rising number of cardiac arrhythmia is expected to drive the market. For instance, according to the CDC 2020 report, more than 750,000 hospitalizations occur each year because of atrial fibrillation. The condition also contributes to nearly 130,000 deaths each year. Thus, the increasing number of cardiac arrhythmia cases is driving the market.

Increasing geriatric population is expected to boost the market over the period of forecast. Many nations are now facing challenges related to the ongoing and increasing demographic shift in age among their populations. As per the Department of Economic and Social Affairs Population Division of United Nations 2019, the global population of 60 years old will double and those of 80 years old will triple in the next 30 years. As per the World Health Organization, the number of people of 65 or older is expected to grow from 524 million in 2010 to 1.5 billion in 2050. Development of several chronic diseases such as cardiovascular diseases and neurodegenerative diseases are often associated with and more common among the older age groups. Thus, the growing geriatric population is driving the market.

The increasing research activities to check the efficacy and safety of ablation devices are expected to boost the market. For instance, on August 19, 2019, Scientists at Johns Hopkins have successfully created personalized digital replicas of the upper chambers of the heart and used them to guide the precise treatment of patients suffering from persistent irregular heartbeats. Also, Loyola tested a new catheter ablation system that can reach deeper into the heart muscle.

Stringent government regulations and side effects are expected to hamper the market growth.

The lack of skilled medical professionals, stringent government regulations, and the onset of side effects are hampering the market. Among these, the onset of side effects is expected to restrain the market. For instance, stroke, chemical allergies, esophageal injury, or in rare cases, death of the complete heart is seen in less percentage of the total population.

Industry Analysis

The global cardiac ablation devices market provides in-depth analysis of the market based on various industry factors such as porter's five forces, regulatory analysis, supply chain analysis, pricing analysis and unmet needs.

Segment Analysis

Radiofrequency ablation devices segment is expected to hold the largest market share in global cardiac ablation devices market

The global cardiac ablation devices market can be segmented by product type into radiofrequency (RF) ablation devices, electrical ablation devices, cryoablation devices, ultrasound ablation devices, and microwave ablation devices.

Electric ablators are further segmented into argon plasma/beam coagulators and irreversible electroporation systems. The electrical ablation devices are expected to grow at a high rate, owing to the increased number of research activities. For instance, according to the researchers, who presented the study details at Heart Rhythm, the Heart Rhythm Society's 39th Annual Scientific Sessions, commenced a first-in-human electroporation ablation study and reported that pulsed electric fields could target the specific tissue for atrial fibrillation.

The cryoablation devices are further segmented into tissue contact probes and tissue spray probes. The cryoablation devices are expected to boost the market, owing to the recent approvals, acquisitions, and mergers by the key players. For instance, In Jan 2021, Medtronic announced that DiamondTemp ablation system got approved by U.S.FDA for treatment of patients that have recurrent, paroxysmal atrial fibrillation.

Ultrasound ablation devices are further segmented into high-intensity focused ultrasound ablators, magnetic resonance-guided focused ultrasound ablators and ultrasound ablation systems. It is expected to drive the market over the period of forecast, owing to the recent government approvals. For instance, in 2019, Acutus Medical won European approval for its AcQMap contact mapping software. The system's novel catheter uses ultrasound and electrical tissue conduction mapping to provide a novel electro physiologic live view inside the heart.

The global cardiac ablation devices market can be segmented by application into cardiac rhythm management, open-heart surgery, and others.

Cardiac Rhythm Management is further segmented into cardiac arrhythmia, atrial fibrillation and flutter, and tachycardia. The cardiac rhythm management segment is expected to boost the market, owing to the increased number of researches, government approvals, etc. Loyola Medicine is among the two centers in the world, offering a novel catheter ablation system used to improve treatment outcomes for a life-threatening heart rhythm disorder called ventricular tachycardia. On January 30, 2019, according to the new research published in the January issue of The Journal of Nuclear Medicine, the Iodine-123 metaiodobenzylguanidine (123I-MIBG) SPECT imaging, when combined with cardiac magnetic resonance imaging (MRI), helped to identify specific subsets of heart tissue more prone to arrhythmia, which may allow physicians to achieve improved ventricular tachycardia suppression and shorter procedure times. Thus, the growing number of research activities are driving the market.

Geographical Analysis

North America region holds the largest market share in the global cardiac ablation devices market

Geographically, the global cardiac ablation devices market is segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America is dominating the global cardiac ablation devices market and is estimated to hold a significant market size over the forecast period owing to the increasing prevalence of cardiac arrhythmia's, presence of well-developed infrastructures, high volumes of catheterization for surgeries, increasing government support, and high patient awareness in the region.

The high volumes of catheterization for surgeries are expected to boost the market. For instance, according to the American Heart Association (AHA), catheter-based ablation procedures boast a 90 % success rate, having a lower risk of complications, and allow patients to resume the normal activities in a few days. Also, the leading companies such as Biosense Webster, Medtronic, and Boston Scientific spend millions of dollars each year researching and developing new devices to improve these success rates and to reduce complications during procedures.

The increasing number of cardiac arrhythmia cases is boosting the market. For instance, the Centre for Disease Control and Prevention in 2019, estimated that 2.7-6.1 million people in the US had atrial fibrillation. Thus, the rising number of cardiac arrhythmia cases are driving the market.

Also, the presence of key players manufacturing cardiac ablation devices are boosting the market. For instance, In Feb 2022, Medtronic announced U.S. FDA approved Freezor and Freezor Xtra cardiac cryoablation focal catheters. These are the first ablation catheters approved by FDA for the treatment of pediatric atrioventricular nodal reentrant tachycardia.

Competitive Landscape

The cardiac ablation devices market is highly competitive with presence of large number of players including Boston Scientific Corporation, Epix Therapeutics, Acutus Medical, Medtronic, AtriCure, Inc., Biosense Webster, Inc., St Jude Medical, Abbott and Mount Sinai Health System Inc.

The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the cardiac ablation devices market globally. For instance,

  • In Aug 2022, Medtronic announced its acquisition of Affere Inc. This acquisition will help metronic expand its portfolio of cardiac ablation by including 1st ever cardiac mapping and navigation platform that will provide integrated diagnostic and radiofrequency ablation solution.
  • In Oct 2021, Boston Scientific announced its acquisition of Baylis Medical Company. It will increase the electrophysiology and heart product portfolio of Boston Scientific.
  • In Jun 2021, Boston Scientific Corp. announced about exercising the acquisition of Farapulse Inc. remaining shares. It will expand Boston electrophysiology portfolio and include Pulse field ablation system of Farapulse. It is a non-thermal ablation system that is used for treating atrial fibrillation.
  • In Jan 2021, Medtronic announced that DiamondTemp ablation system got approved by U.S.FDA for treatment of patients that have recurrent, paroxysmal atrial fibrillation. It is the 1st FDA approved irrigated radiofrequency ablation system that is temperature controlled.

Key Companies to Watch

Boston Scientific Corporation:

Overview: Boston is a multinational biomedical engineering company. It manufactures medical devices that includes interventional cardiology, neurovascular intervention, cardiac surgery, oncology, vascular surgery etc. it also offers minimally invasive implantable cardiovascular defibrillator. It was founded in 1979 and is headquartered in Massachusetts, United States.

Product Portfolio:

MetriQ Pump: It is an open irrigated system that enables ablation procedures. It helps in maximizing the success of open irrigated procedure. With advanced ablation technology it improves patient outcomes.

Key Developments: In Jan 2021, Boston Scientific Corp. announced its agreement of acquisition of Preventice Solutions Inc., a private company that provides products of mobile cardiac health solutions and services.

The global cardiac ablation devices market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising incidences of cardiac arrhythmia
      • 4.1.1.2. The growing number of geriatric populations
    • 4.1.2. Restraints
      • 4.1.2.1. The onset of side effects
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Supply Chain Analysis
  • 5.4. Pricing Analysis
  • 5.5. Unmet Needs

6. By Product type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 6.1.2. Market Attractiveness Index, By Product type Segment
  • 6.2. Radiofrequency (RF) Ablation
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.2.2.1. Temperature-controlled Radiofrequency Ablators
      • 6.2.2.2. Fluid-cooled Radiofrequency Ablators
      • 6.2.2.3. Robotic Catheter Manipulation Systems
  • 6.3. Electrical Ablation
    • 6.3.1. Introduction
    • 6.3.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.3.2.1. Argon Plasma/Beam Coagulators
      • 6.3.2.2. Irreversible Electroporation Systems
  • 6.4. Cryoablation
    • 6.4.1. Introduction
    • 6.4.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.4.2.1. Tissue Contact Probes
      • 6.4.2.2. Tissue Spray Probes
  • 6.5. Ultrasound Ablation
    • 6.5.1. Introduction
    • 6.5.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.5.2.1. High-intensity Focused Ultrasound Ablators
      • 6.5.2.2. Magnetic Resonance Guided Focused Ultrasound Ablators
      • 6.5.2.3. Ultrasound Ablation Systems
  • 6.6. Microwave Ablation
    • 6.6.1. Introduction
    • 6.6.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 6.6.2.1. Microwave Thermotherapy Devices

7. By Application

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 7.1.2. Market Attractiveness Index, By Application Segment
  • 7.2. Cardiac rhythm management
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
      • 7.2.2.1. Cardiac Arrhythmia
      • 7.2.2.2. Atrial Fibrillation and Flutter
      • 7.2.2.3. Tachycardia
  • 7.3. Open surgery
  • 7.4. Others

8. By End-user

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 8.1.2. Market Attractiveness Index, By End-user Segment
  • 8.2. Hospitals
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2018-2028
  • 8.3. Ambulatory surgical centers
  • 8.4. Clinics
  • 8.5. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. The U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. The U.K.
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user
    • 9.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. Australia
      • 9.5.6.5. Rest of Asia Pacific
  • 9.6. The Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product type
    • 9.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 9.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End-user

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Boston Scientific Corporation
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Key Highlights
    • 11.1.4. Financial Overview
  • 11.2. Epix Therapeutics
  • 11.3. Acutus Medical
  • 11.4. Medtronic
  • 11.5. AtriCure, Inc.
  • 11.6. Biosense Webster, Inc.
  • 11.7. St Jude Medical
  • 11.8. Abbott
  • 11.9. Mount Sinai Health System Inc

LIST NOT EXHAUSTIVE

12. Global Cardiac Ablation Devices Market - DataM

  • 12.1. Appendix
  • 12.2. About Us and Method of Fixation
  • 12.3. Contact Us